Patents by Inventor Mark Jonathan Main

Mark Jonathan Main has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHALABLE POWDER COMPOSITION COMPRISING IL-13 ANTIBODY
    Publication number: 20190247303
    Abstract: An inhalable powder composition comprises a) an antagonistic antibody which binds human IL-13, b) leucine and c) trehalose. The antibody may comprise a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:3 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:1. Also described is the use of such compositions in the treatment of asthma, as well as inhalers containing such compositions.
    Type: Application
    Filed: October 31, 2017
    Publication date: August 15, 2019
    Inventors: Frazer Giles MORGAN, Mark Jonathan MAIN, Roger PALFRAMAN, David KIRKE
  • COMPOSITIONS AND USES
    Publication number: 20130287854
    Abstract: According to the invention there is provided a method of treating and/or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and/or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation.
    Type: Application
    Filed: November 15, 2011
    Publication date: October 31, 2013
    Applicant: VECTURA LIMITED
    Inventors: Frazer Giles Morgan, Mark Jonathan Main
  • PULMONARY FORMULATIONS OF TRIPTANS
    Publication number: 20110077272
    Abstract: A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route.
    Type: Application
    Filed: February 2, 2009
    Publication date: March 31, 2011
    Applicant: Vectura Limited
    Inventor: Mark Jonathan Main
  • COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
    Publication number: 20100288276
    Abstract: The present invention relates to improved treatment of diseases and disorders of the central nervous system by administration of apomorphine. In particular, the administration is via pulmonary inhalation. The invention provides the means for improving the treatment of a number of conditions, including Parkinson's Disease.
    Type: Application
    Filed: October 31, 2008
    Publication date: November 18, 2010
    Applicant: VECTURAL LIMITED
    Inventors: David Ganderton, Mark Jonathan Main, Frazer Giles Morgan
  • Pharmaceutical compositions
    Publication number: 20090068276
    Abstract: The present invention relates to new pharmaceutical formulations comprising pharmaceutically active agents which can induce one or more involuntary coughs in a patient when administered as conventional formulations and/or via conventional routes. Formulations are provided comprising a cough-inducing pharmaceutically active agent, wherein the formulation may be administered by pulmonary inhalation without inducing a cough. Alternatively, formulations are provided for administering the cough-inducing active agent via an alternative route.
    Type: Application
    Filed: May 22, 2008
    Publication date: March 12, 2009
    Applicant: Vectura Group plc
    Inventors: Mark Jonathan Main, Martin James Oliver, Timothy Wright